Pharma Research (CEO Shin-gyu Kim and Ki-seok Kang) published two international academic papers stating that the immune booster Zadaxin enhances the therapeutic effect of immuno-cancer drugs. The key points of these papers are that when Zadaxin and immunotherapy are administered in combination, overall survival (OS) improvement of patients and inhibition of cancer tumor invasion and metastasis appear.
According to a clinical paper published in ‘Expert Opinion on Biological Therapy’, an SCI-E-level medical journal in 2018, patients who received immunotherapy alone (Yervoy) for 61 melanoma patients. The average survival period of patients who received Zadaxin before administration of immunotherapy was 38.4 months, which was about a 5-fold difference. The survival rate up to 20 months was slightly higher than that of the Zadaxin group, but it was found that the survival rate for the entire period after that had doubled significantly.
In addition, in the paper ‘Oncotargets and therapy’, a 2018 SCI-E grade medical journal, the metastasis and inhibitory effect of Zadakcin on cancer tumors was confirmed. When immunotherapy and thymosin alpha 1 (Zadaxin) were co-administered to non-small cell lung cancer cells (H1299, NL9980, etc.), the lung cancer cell invasion rate was reduced to a quarter of that of the control group, and the metastasis rate was reduced by half. . When thymosin alpha 1 treatment was performed on animals separately inoculated with non-small cell lung cancer cells, the incidence of lesions due to cancer cell metastasis fell to less than a quarter of that of the control group.
Therefore, the paper analyzed that thymosin alpha 1 inhibits the invasion and metastasis activity by blocking the PD-L1-related signal (STAT3-MMP2) in non-small cell lung cancer with high PD-L1 expression. PD-L1 is a protein on the surface of cancer cells and is a major factor in evading the attack of T cells, which are immune cells.
An official from Pharma Research said, “Amid the global boom in the development and clinical trials of third-generation immuno-oncology drugs, the fact that thymosin alpha 1 is highly effective as an adjuvant therapy for immunotherapy as well as conventional chemotherapy has been confirmed through a number of international academic journals. ” he said.
On the other hand, Zadaxin has been designated as an orphan drug by the US FDA and European EMA, and is being licensed and supplied in over 40 countries around the world.
